Safety of long-term treatment of HAM/TSP patients with valproic acid

S. Olindo, G. Belrose, N. Gillet, S. Rodriguez, Mathieu Boxus, O. Verlaeten, B. Asquith, C. R. M. Bangham, A. Signaté, D. Smadja, A. Lezin, R. Césaire, L. Willems

Research output: Contribution to journalArticlepeer-review


[en] HTLV-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) is a neurodegenerative disease of the central nervous system induced by Human T lymphotropic virus type 1 (HTLV-1). As a potential therapeutic approach, we previously suggested reducing the proviral load (PVL) by modulating lysine deacetylase activity using valproic acid (VPA) and exposing virus-positive cells to the host immune response. We conducted a single-center, two-year open-label trial, with 19 HAM/TSP volunteers treated with oral VPA. PVL, CD38/HLA-DR expression and CD8+ lysis efficiency were not significantly affected by VPA. Mean scores of HAM/TSP disability did not differ between baseline and final visit. Walking Time Test (WTT) increased significantly (>20 in 3 patients and was in keeping with minor VPA side effects (drowsiness and tremor). WTT improved rapidly after VPA discontinuation. We conclude that long term treatment with VPA is safe in HAM/TSP.
Original languageEnglish
Pages (from-to)6306-6309
Number of pages4
Issue number24
Publication statusPublished - 2011
Externally publishedYes


  • Sciences de la santé humaine => Oncologie

Fingerprint Dive into the research topics of 'Safety of long-term treatment of HAM/TSP patients with valproic acid'. Together they form a unique fingerprint.

Cite this